The Japanese group licenses sapablursen from Ionis for $280m.
ApexOnco Front Page
Recent articles
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.
Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
